Avsar.

Healthcare · Pharmaceuticals

Aarti Pharmalabs Ltd (AARTIPHARM)

₹862.65

Mkt cap
₹7,788 Cr
P/E ratio
36.20
P/B
3.69
Div yield
0.41%
ROE
8.59%
ROCE
10.70%
EPS (TTM)
₹23.83
Book value
₹234
52W range
592–940
Sector
Healthcare

Price history

Previous close

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals [1]

NSE AARTIPHARMBSE 543748
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−8.18% from high
₹863
₹592+45.73% from low₹940
Current
₹862.65
Prev close
₹856.25
Day
+0.75%
Price performance
1D
+0.75%
1W
+2.04%
1M
+25.78%
3M
+37.97%
6M
+27.26%
1Y
+0.23%
YTD
+16.24%

Financials

Revenue, profit & margin
P/E ratio
36.2×
AARTIPHARM is 7% above the sector median of 34.0×
AARTIPHARM36.2×
Sector median34.0×
 Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales458440449506555458538564386418432583536
Expenses373352353388459364409418293344330470400
Operating Profit85889611896941291469374102113136
OPM %19%20%21%23%17%20%24%26%24%18%24%19%25%
Other Income0112245-2202148
Interest444556107711131713
Depreciation17181919202123232325292830
Profit before tax64677496747210111565396382101
Tax %26%23%29%32%25%24%26%23%24%28%24%25%25%
Net Profit47525365555574885028486176
EPS in Rs5.205.725.827.206.126.038.169.755.463.085.296.748.40
Raw PDF

Earnings

Results dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +20.00% · closed higher next day 1 of last 1
 Q1FY27
Broadcast7 Aug '26◦
Earnings day+20.00%
+1 day+28.85%
+5 days+25.68%
+15 days+23.26%
+30 days—
FilingXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Jun 2026
42.86%Promoter
Promoters42.86%0.22
FIIs8.17%0.22
DIIs7.22%0.18
Public41.74%0.64
Government0.01%
Ownership trend

Peers

8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
SUNPHARMA₹1,899.0036.074,55,6340.84%2,901+5.95%15,300+10.46%20.53%
DIVISLAB₹9,100.0081.092,41,5760.33%902+65.50%3,080+27.80%21.97%
TORNTPHARM₹4,857.0082.801,84,7450.78%566+5.79%4,921+54.85%15.19%
CIPLA₹1,385.0031.261,11,8880.94%786−39.19%7,119+2.33%15.49%
ZYDUSLIFE₹1,120.0022.951,11,7200.09%990−35.09%8,017+21.96%21.14%
LAURUSLABS₹1,840.0090.9399,4170.11%362+125.49%2,026+29.10%17.76%
LUPIN₹2,110.0016.2096,4830.85%1,417+16.08%8,277+32.04%29.93%
AARTIPHARM₹858.8036.187,7880.41%76+53.82%536+38.74%10.70%
Median: 158 Co.₹421.5033.962,2770.08%13+30.25%164+18.67%14.96%

Filings

Annual reports4
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bse
Concall transcripts38
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTSep 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024
Credit ratings6
Rating update 13 MarcrisilRating update 17 Jul 2025crisilRating update 17 Mar 2025crisilRating update 26 Jun 2024crisilRating update 8 May 2024crisilRating update 21 Feb 2023crisil
Announcements5
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 2 Sep - Gandhinagar stamp authority levies Rs.59.5 crore duty and penalty on demerger scheme order.Announcement under Regulation 30 (LODR)-Change in Management 31 Aug - G.M. Naidu resigns as Manufacturing/Sr General Manager, effective August 31, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 30 AugBusiness Responsibility and Sustainability Reporting (BRSR) 29 Aug - Aarti Pharmalabs submitted its FY2025-26 BRSR, including ESG disclosures and a ₹31.16 lakh CGST/SGST demand.Notice Of 7Th Annual General Meeting Of The Company 29 Aug